2 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)Active, not recruitingPhase 2 / Phase 32026-08-20NCT06957080
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in JapanHemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmActive, not recruitingNot stated2026-01-02NCT05228158